Stock Research: Pacira BioSciences

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Pacira BioSciences

NasdaqGS:PCRX US6951271005
86
  • Value
    82
  • Growth
    80
  • Safety
    Safety
    86
  • Combined
    100
  • Sentiment
    22
  • 360° View
    360° View
    86
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Pacira BioSciences is a pharmaceutical company specializing in non-opioid treatments for pain management. The company operates in the pharmaceutical industry, with key products including EXPAREL, ZILRETTA, and iovera. Pacira BioSciences operates in the US. In the last fiscal year, the company had 790 employees, a market cap of $1,060 million, profits of $531 million, and revenue of $701 million.

more
Index
NASDAQ
D.J. US Pharmaceutical
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 8-Jan-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
82 74 49 29
Growth
80 67 79 65
Safety
Safety
86 79 58 61
Sentiment
22 44 75 30
360° View
360° View
86 91 91 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
10 11 64 43
Opinions Change
50 82 50 11
Pro Holdings
n/a 82 63 61
Market Pulse
29 19 63 70
Sentiment
22 44 75 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
82 74 49 29
Growth
80 67 79 65
Safety Safety
86 79 58 61
Combined
100 100 81 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
72 57 46 30
Price vs. Earnings (P/E)
89 90 75 63
Price vs. Book (P/B)
65 61 50 38
Dividend Yield
1 1 1 1
Value
82 74 49 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
61 54 64 69
Profit Growth
28 43 60 71
Capital Growth
97 94 78 31
Stock Returns
65 39 47 55
Growth
80 67 79 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
44 49 36 42
Refinancing
76 67 59 51
Liquidity
72 66 64 65
Safety Safety
86 79 58 61

Similar Stocks

Discover high‑ranked alternatives to Pacira BioSciences and broaden your portfolio horizons.

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cigna

NYSE:CI
Country: USA
Industry: Health Care Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock has excellent financial qualities (value, growth, and safety are high) but a negative professional market sentiment. It suits an investor who believes the negative sentiment is a temporary overreaction and is looking for a financially solid company.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: